Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC lessened its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 12.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 531,286 shares of the company's stock after selling 77,582 shares during the period. ArrowMark Colorado Holdings LLC owned approximately 0.74% of Kiniksa Pharmaceuticals worth $13,277,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company's stock worth $58,833,000 after buying an additional 16,595 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter worth $71,000. Linden Thomas Advisory Services LLC grew its stake in shares of Kiniksa Pharmaceuticals by 1.7% during the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company's stock worth $2,209,000 after purchasing an additional 1,921 shares in the last quarter. SG Americas Securities LLC increased its holdings in Kiniksa Pharmaceuticals by 261.3% in the second quarter. SG Americas Securities LLC now owns 69,226 shares of the company's stock valued at $1,292,000 after buying an additional 50,066 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Kiniksa Pharmaceuticals by 45.7% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 181,966 shares of the company's stock valued at $3,397,000 after buying an additional 57,088 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Finally, Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Price Performance

KNSA traded down $0.71 during trading on Tuesday, reaching $21.14. 94,254 shares of the stock were exchanged, compared to its average volume of 401,484. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.47 and a 1 year high of $28.15. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -156.06 and a beta of 0.27. The business's 50 day moving average price is $23.90 and its two-hundred day moving average price is $22.99.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the prior year, the company earned ($0.20) earnings per share. The firm's revenue for the quarter was up 67.4% compared to the same quarter last year. On average, analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now owns 116,975 shares of the company's stock, valued at $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.